Vocal fold paralysis is not a rare clinical entity. It may be caused via head and neck injuries, tumors, disease, surgery, or stroke. Medialization Thyroplasty (MT) is the gold standard treatment for glottis insufficiency, by inserting alloplastic or autologous materials into the paraglottic space to achieve glottis closure. In patients with a large glottis gap or high vagal lesions, Arytenoid Adduction (AA) can be performed to reduce the posterior glottis gap and correct the vertical height difference between the vocal folds. APrevent VOIS is designed to fit individual needs and greatly improves the quality of life.

APrevent VOIS is the first and only implant in the world that can be adjusted both intra- and postoperatively to satisfy individual needs. VOIS's concept and design of the implant mimics actual physiological mechanism (arytenoid rotation) to deliver better therapeutic result especially in the closure of the posterior glottis. The surgical procedure is similar to current one so it's easy to perform and resulting in a low learning curve for surgeons. Its adjustable functionality significantly reduces surgery time, operating room resource consumption, and patient risks, while also lowering the overall difficulty of the procedure. No revision surgeries needed for under- or overcorrection. Postoperative adjustments can be made minimally invasively in an outpatient setting, allowing the patient's vocal folds and voice to remain in optimal condition.

The APrevent VOIS has been highly praised by numerous international Key Opinion Leaders (KOLs), establishing itself as a product with strong market necessity and competitiveness. It has obtained CE certification, along with certificate in Switzerland, the UK, Taiwan, Australia, Malaysia, Indonesia, and Thailand. Additionally, it's able to been reimbursed in Austria, MMalaysia, Indonesia, and Thailand. Additionally, it's able to been reimbursed in Austria, Germany, the UK, Switzerland, and Finland.